DXCM AI Stock Analysis – Buy, Hold, or Avoid?
DexCom, Inc. (DXCM)
Fundamentals
DexCom, Inc. exhibits strong and consistent financial performance driven by robust revenue growth and improving profitability margins. The company maintains a solid position in the continuous glucose monitoring market with expanding earnings and positive recent quarterly results exceeding estimates, signaling efficient execution and growth sustainability.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
13.08% YoY
Q2 2026
Net Income
38.54% YoY
Q2 2026
Net Margin
Q2 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q2 2026
Net Income Growth YoY
Latest Quarter: Q2 2026
Revenue Per Share Growth YoY
Latest Quarter: Q2 2026
EPS Growth YoY
Latest Quarter: Q2 2026
Book Value Per Share Growth YoY
Latest Quarter: Q2 2026
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.2B | 1.3B | 1.2B | 1.2B | 1.0B | 1.1B | 994.2M |
| Revenue Growth YoY | +13.08% | +15.05% | +13.12% | +21.64% | +15.21% | +12.49% | +7.64% | +1.97% |
| Net Income | 249.1M | 199.5M | 267.3M | 283.8M | 179.8M | 105.4M | 151.7M | 134.6M |
| Net Income Growth YoY | +38.54% | +89.28% | +76.20% | +110.85% | +25.30% | -28.01% | -40.81% | +11.52% |
| EPS | $0.65 | $0.52 | $0.69 | $0.73 | $0.46 | $0.27 | $0.39 | $0.35 |
| EPS Growth YoY | +41.30% | +92.59% | +76.92% | +108.57% | +27.78% | -28.95% | -41.79% | +12.90% |
Profitability Metrics
Technical Analysis
Unable to retrieve current technical indicator data for DXCM due to a data fetch issue. Based on available price action and volume, DXCM shows strong bullish momentum with a recent sharp price increase nearing its 52-week high. However, without detailed RSI, moving averages, and other indicators, analysis is limited to chart patterns and recent price levels.
Watch for pullback
Price in uptrend
Range-bound market
50 above 200 - bullish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
DexCom, Inc. exhibits strong and consistent financial performance driven by robust revenue growth and improving profitability margins. The company maintains a solid position in the continuous glucose monitoring market with expanding earnings and positive recent quarterly results exceeding estimates, signaling efficient execution and growth sustainability.
Latest Earnings
Q2 2026 Earnings (Jun 30, 2026)
Earnings Per Share (EPS)
Actual
$0.70
Estimated
$0.61
Surprise
+$0.09
Surprise %
+14.57%
Revenue
Actual
$1.31B
Estimated
$1.29B
Surprise
+$18.08M
Surprise %
+1.40%
Historical Earnings
| Q2 2026 | Q1 2026 | Q4 2025 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $0.70 | $0.56 | $0.68 | $0.68 | $0.61 | $0.48 | $0.32 | $0.45 |
| EPS (Estimated) | $0.61 | $0.47 | $0.65 | $0.65 | $0.58 | $0.44 | $0.33 | $0.48 |
| EPS Surprise | +$0.09 | +$0.09 | +$0.03 | +$0.03 | +$0.03 | +$0.04 | -$0.01 | -$0.03 |
| % Diff | +14.6% | +20.3% | +4.6% | +4.6% | +5.9% | +8.2% | -2.2% | -6.1% |
| Revenue | ||||||||
| Revenue (Actual) | $1.31B | $1.19B | $1.26B | $1.26B | $1.21B | $1.16B | $1.04B | $1.11B |
| Revenue (Estimated) | $1.29B | $1.17B | $1.25B | $1.18B | $1.18B | $1.12B | $1.02B | $1.11B |
| Revenue Surprise | +$18.08M | +$17.22M | +$11.33M | +$76.67M | +$25.56M | +$32.49M | +$18.59M | +$4.35M |
| % Diff | +1.4% | +1.5% | +0.9% | +6.5% | +2.2% | +2.9% | +1.8% | +0.4% |
Valuation
DexCom (DXCM) currently trades with valuation metrics reflecting a premium relative to many of its healthcare medical device peers, supported by solid earnings growth and strong gross margins. Analyst consensus leans positive with price targets slightly above the current price, suggesting moderate upside potential driven by growth prospects in the continuous glucose monitoring market.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 25.90 | 30.19 | 24.05 | 23.04 | 47.44 | 63.23 | 49.85 | 47.89 |
| Price to Sales | 19.75 | 20.29 | 20.38 | 21.76 | 29.58 | 25.78 | 27.89 | 26.58 |
| Price to Book | 9.86 | 8.18 | 9.35 | 9.65 | 13.30 | 11.78 | 14.77 | 13.35 |
| Enterprise Value to EBITDA | 67.10 | 71.98 | 63.73 | 64.33 | 115.44 | 129.62 | 120.57 | 119.62 |
| Enterprise Value to Revenue | 19.94 | 20.51 | 20.75 | 22.37 | 30.81 | 27.40 | 29.67 | 28.56 |
Sentiment & Analyst Ratings
DexCom (DXCM) enjoys overwhelmingly positive market sentiment fueled by strong Q2 2026 earnings and raised full-year revenue guidance. Analysts have largely maintained or raised buy ratings and price targets, reflecting confidence in sustained demand for its continuous glucose monitoring products and ongoing technological innovations. However, insider selling and some valuation caution provide a slight counterbalance to the bullish outlook.
Analyst Recommendations
Risk Assessment
DexCom (DXCM) demonstrates solid financial health with strong liquidity and manageable leverage, positioning it well to meet short-term obligations and service debt comfortably. Nevertheless, risks including patent litigation, stock price volatility, and rising operating expenses warrant caution. Compared to sector peers, DexCom maintains a moderate risk profile with an improving liquidity trend and sustainable capital structure.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q2 2026
Quick Ratio
Latest Quarter: Q2 2026
Debt-to-Equity
Latest Quarter: Q2 2026
Debt-to-Assets
Latest Quarter: Q2 2026
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.73 | 1.95 | 1.88 | 1.56 | 1.52 | 1.50 | 1.47 | 2.46 |
| Quick Ratio | 1.43 | 1.64 | 1.59 | 1.38 | 1.35 | 1.32 | 1.28 | 2.12 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.51 | 0.47 | 0.51 | 0.94 | 1.00 | 1.14 | 1.23 | 1.31 |
| Debt-to-Assets | 0.21 | 0.21 | 0.22 | 0.34 | 0.35 | 0.38 | 0.40 | 0.41 |
Liquidity Assessment
Current Ratio: 1.73(Strong)
Quick Ratio: 1.43(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.51(Moderate)
Debt-to-Assets: 0.21(Low)
The company maintains a balanced capital structure with manageable debt levels.
Frequently Asked Questions about DXCM
AI Answers: Common Questions About DXCM
Get AI-powered answers to the questions investors ask most about DexCom, Inc.
Yes, DexCom is a good buy with a P/E of 35.82 supported by 14-16% revenue growth and expanding operating margins above 24%. Recent Q2 earnings beat and raised guidance reinforce its growth trajectory.
No, current data does not support selling. Strong fundamentals, positive technical momentum near 52-week highs, and bullish sentiment outweigh risks. Monitor legal developments and valuation closely.
Key risks include patent litigation with Abbott, pricing and reimbursement pressures, regulatory hurdles, and rising operating expenses that could impact margins and growth.
Analyst price targets post-earnings cluster near or above $90, with technical upside potential if the stock breaks above the $84.70 52-week high resistance.
DexCom is fairly valued with premium EV/EBITDA and P/S multiples justified by sustained double-digit growth, strong margins, and market leadership in CGM technology.
Fundamentals are strong with $1.31B Q2 revenue (+14% YoY), EPS of $0.70 beating estimates, gross margins near 64%, and improving operating income margins above 24%.
Technically bullish with a recent 11.95% price surge on doubled volume near all-time highs. Potential breakout above $84.70 resistance could drive price toward $90 short-term.
Upcoming catalysts include FDA regulatory decisions, new product launches like the G7 15-day system, and expanded reimbursement coverage expected by year-end 2026.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.